<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233947</url>
  </required_header>
  <id_info>
    <org_study_id>TG-AFP-003</org_study_id>
    <nct_id>NCT01233947</nct_id>
  </id_info>
  <brief_title>Study of AFP464 +/- Faslodex in ER + Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tigris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tigris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AFP464 is an investigational agent which may be effective in the treatment of cancer. The
      purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label study. Patients will be randomized in a 1:1 ratio to single
      arm AFP464, or AFP464+Faslodex. Patients will be treated until disease progression is noted.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Response</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Benefit Response (CBR) defined as Complete Response, Partial Response or Stable Disease for 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the number of patients who experience adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>AFP464</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AFP464 + Faslodex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFP464</intervention_name>
    <description>AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle</description>
    <arm_group_label>AFP464</arm_group_label>
    <other_name>(aminoflavone)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFP464 + Faslodex</intervention_name>
    <description>AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label</description>
    <arm_group_label>AFP464 + Faslodex</arm_group_label>
    <other_name>(aminoflavone) + (Fulvestrant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable
             disease or evaluable disease with serum CA27.29&gt;=50 U/mL; adequate bone marrow, liver
             and renal function; DLco grade 0 or 1.

        Exclusion Criteria:

          -  HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain
             metastases,
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne L. Blume, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Oncology-Baylor Charles A. Sammons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>January 6, 2012</last_update_submitted>
  <last_update_submitted_qc>January 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2012</last_update_posted>
  <responsible_party>
    <name_title>Binh Nguyen, MD PhD / Chief Medical Officer</name_title>
    <organization>Tigris Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

